Chronic Lymphocytic Leukemia, Hodgkin Disease, Leukemia, Lymphoblastic, Acute, Leukemia, Myeloid, Acute, Lymphoma, Non-Hodgkin, Myelodysplastic Syndromes
Conditions
Brief summary
The purpose of this study is to determine the safety and feasibility of unrelated double and single cord blood transplantation in patients with haematological malignancies using reduced-intensity or myeloablative conditioning regimens.
Interventions
DRUGThiotepa
DRUGFludarabine
DRUGIntravenous busulphan
DRUGThymoglobulin
DRUGCiclosporin
DRUGMycophenolate mofetil (MMF)
DRUGCyclophosphamide
RADIATIONRadiotherapy
DRUGMelphalan
Sponsors
King's College Hospital NHS Trust
Study design
Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 70 Years
Healthy volunteers
No
Inclusion criteria
DISEASE INCLUSION CRITERIA: In general this encompasses all haematological disorders where a volunteer unrelated donor transplant is clinically indicated. 1. Acute, chronic leukaemia or myelodysplastic syndrome for which allogeneic transplantation is considered as the best treatment option. 1. Acute myeloid leukaemia (AML) in first complete remission (CR1) with one of the following characteristics: * High risk cytogenetic or molecular alterations (e.g. t(9;22), deletion 7/7q-, monosomy 5 or del(5q), 3q26 alterations, complex karyotype \[3 or more anomalies\], p53 alterations, 11q23 especially t(6;11) abnormalities, FLT-3 ITD) * Leukocytes at diagnosis \> 50 x109/l (except in cases with good prognosis molecular rearrangements for which leukocytes should be \> 100 x 109/l) 2. Myelodysplastic syndromes * International Prognosis Index (IPSS) above 1 (intermediate group 2 or high risk) * IPSS 0 or 0.5 in the presence of cytopenias requiring treatment. 3. Therapy related AML or MDS in first CR 4. AML or MDS in second (CR2) or subsequent CR 5. Ph'-positive chronic myeloid leukaemia i. In first chronic phase if refractory and/or intolerance to tyrosine kinase inhibitors is clearly demonstrated ii. In second chronic phase 2. Acute lymphoblastic leukaemia (ALL) a. In CR1 with one of the following characteristics: i. Very high risk chromosome or molecular alterations (e.g. t(9;22), t(4;11), complex karyotype in adults, bcr/abl rearrangements, MLL rearrangements) ii. Slow response to induction treatment defined as the presence of \>10% blasts in bone marrow at day 14 of induction treatment iii. Adults aged \> 30 years iv. Adults with B ALL cell line with a number of leukocytes at diagnosis \>25 x 109/L or T ALL cell line with a number of leukocytes at diagnosis \>100X109/L b. In CR2 or subsequent CR 3. Non-Hodgkin's lymphoma 1. Follicular NHL: in second or subsequent complete or partial remission 2. Mantle cell NHL: in second or subsequent complete or partial remission 3. High grade NHL: in second complete or very good partial remission 4. Hodgkin's disease a. in second or subsequent complete or partial remission 5. Chronic lymphocytic leukaemia. 1. in second or subsequent remission 2. with adverse risk prognostic features in first remission 6. Acquired bone marrow failure syndromes 7. Other haematological malignancies for which UD bone marrow transplantation is indicated PATIENT SELECTION Inclusion criteria: myeloablative conditioning regimen 1. Aged under 35 years and greater than 18 years 2. Absence of HLA compatible related donor. 3. Need for an urgent transplantation or absence of HLA-compatible VUD after searching the international registries. 4. Patients with a HLA-compatible VUD but whose donor is considered by the transplantation centre as unsuitable will also be eligible. 5. Availability of suitable UD-UCB unit/s. 6. Informed consent.
Exclusion criteria
myeloablative conditioning regimen 1. Patients with an available 5-6/6 HLA-A, -B, -DRB1 matched sibling donor or 10/10 unrelated bone marrow donor 2. ECOG performance status worse than 2 3. Cardiac insufficiency requiring treatment, symptomatic coronary artery disease or LVEF less than 40%. 4. Hepatic disease, with total bilirubin above 20umol/l or AST \> 3 times upper limit of normal. 5. Severe hypoxaemia, pO2 \< 70 mm Hg, with decreased DLCO \< 70% of predicted; or mild hypoxemia, pO2 \< 80 mm Hg with severely decreased DLCO \< 60% of predicted. 6. Impaired renal function (creatinine \> 2 times upper limit of normal or creatinine clearance \< 50% for age, gender, weight). 7. Patients who have received previous treatment with Thymoglobulin® 8. HIV or HTLV positive patients. 9. Female patients who are pregnant or breast feeding due to risks to foetus from conditioning regimen and potential risks to nursing infants. 10. Life expectancy severely limited by diseases other than the disease indication for transplant 11. Serious concurrent untreated infection e.g. active tuberculosis, mycoses or viral infection 12. Serious psychiatric/ psychological disorders 13. Absence of /inability to provide informed consent 14. Serious diseases that prevent treatments with chemotherapy 15. Myelofibrosis Inclusion criteria: reduced-intensity conditioning regimen (For both FluMel & FluCyTBI regimens): 1. Age under 70 years and older than 18 years 2. Absence of HLA compatible related donor. 3. Need for an urgent transplantation or absence of HLA-compatible VUD after searching the international registries. 4. Patients with a HLA-compatible VUD but whose donor is considered by the transplantation centre as unsuitable will also be eligible. 5. Availability of suitable UD-UCB unit/s. 6. Informed consent.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Treatment related mortality at day 100 | Day 100 |
Secondary
| Measure | Time frame |
|---|---|
| Chimerism | Days 14 (myeloblative conditioning only), 28, 56, 100 and months 6 and 12 |
| Incidence of neutrophil engraftment by day 42 | Days 14, 28 and 42 |
| Incidence of platelet engraftment by 6 months | Days 14, 28, 56, 100 and month 6 |
| Incidence of grade II-IV and III-IV acute GVHD | Days 28, 56, 100 and months 6, 9, 12, 18 and 24 |
| Incidence of chronic GVHD during the first year | Day 100 and months 6 and 12 |
| One year overall survival for each treatment cohort | 1 year |
| Incidence of systemic infections | Twice a week pre-transplant to day 100 then weekly or as clinically indicated |
| Disease free survival at one year post-transplant for each cohort | 1 year |
| Immune reconstitution | Days 14, 28, 56, 100 and months 6, 9, 12, 18 and 24 |
| Dynamics of EBV infection and immunity following cord blood transplantation | Days 14, 28, 56, 100 and months 6, 9 and 12 |
| The development (if any) of transplant associated post transplant lymphoproliferative disease (PTLD) | Days 14, 28, 56, 100 and months 6, 9 and 12 |
| Identify any possible predictive markers for patients most at risk of PTLD development | Days 14, 28, 56, 100 and months 6, 9 and 12 |
| Quality of life | Pre-transplant and months 6, 12, 18 and 24 |
| Incidence of one year relapse or disease progression for each treatment cohort | 1 year |
| Incidence of CMV, adenovirus and EBV activation | Twice a week pre-transplant to day 100 then weekly or as clinically indicated |
Countries
United Kingdom
Outcome results
None listed